KPV 10 mg— Research Protocol

Quickstart Highlights

KPV (Lysine–Proline–Valine) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH) studied for its potent anti‑inflammatory properties without melanotropic side effects^[1][2]. Research demonstrates KPV reduces pro‑inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation^[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for precise insulin‑syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
• Typical daily range: 200–500 mcg once daily (gradual titration recommended).
• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Phase	Dose	Units (per injection)
Week 1	200 mcg	6 units (0.06 mL)
Week 2	300 mcg	9 units (0.09 mL)
Week 3	400 mcg	12 units (0.12 mL)
Weeks 4–8	500 mcg	15 units (0.15 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to maintain manageable injection volumes. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability and more precise measurement^[10].

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl/roll until dissolved (do not shake).
4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (KPV, 10 mg each):
  • 8 weeks ≈ 3 vials
  • 12 weeks ≈ 4 vials
  • 16 weeks ≈ 6 vials

• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes

• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
  • 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles

• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Protocol Overview

Concise summary of the once‑daily regimen.

• Goal: Support reduction of systemic inflammation and modulate immune responses without melanotropic effects^[1][3].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 200–500 mcg daily with gradual weekly titration.
• Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen at −20 °C (−4 °F) or below; reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

• Start: 200 mcg daily; increase by ~100 mcg weekly as tolerated^[4][5].
• Target: 400–500 mcg daily by Weeks 4–8 for maintenance anti‑inflammatory effects.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks under monitoring.
• Timing: Any consistent time; rotate injection sites systematically.

Storage Instructions

Proper storage preserves peptide quality and stability.

• Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; protect from moisture and light^[6][7].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days^[7].
• Allow vials to reach room temperature before opening to minimize condensation uptake.
• Avoid freeze–thaw cycles: Do not refreeze reconstituted peptide solutions; prepare aliquots if long‑term storage is needed^[6].

How It Works

KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects^[1][2]. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation^[3]. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release^[2]. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols^[4].

Potential Benefits & Side Effects

Observations from preclinical and early‑stage research.

• Anti‑inflammatory activity: Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation^[3].
• Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability^[4].
• Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation^[5].
• Generally well tolerated: Occasional mild injection‑site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols.
• No melanotropic effects: Unlike full α‑MSH, KPV does not affect melanocyte activity or skin pigmentation^[1].

References

• Journal of Pharmaceutical Drug Delivery Research (2022)Pawar K. et al.: KPV as an α‑MSH fragment retains potent anti‑inflammatory activity without melanotropic side effects
• Gastroenterology (2008)Dalmasso G. et al.: PepT1‑mediated tripeptide KPV uptake reduces intestinal inflammation in DSS colitis models
• Innerbody Research (2025)KPV peptide benefits, safety, and administration routes; subcutaneous injection for systemic therapy
• Peptides.org Dosage Guide (2023)KPV dosage calculator and protocol: 200–400 mcg subcutaneously once daily for inflammation and wound healing
• Bachem (Peptide Handling Guidelines)Long‑term peptide stability best achieved in lyophilized form at <−15 °C; avoid extended storage in solution
• PeptideSciences (Storage Guidelines)Lyophilized peptides stable for short‑term at 4 °C, long‑term at −20 °C; reconstituted solutions refrigerated up to ~30 days
• Johns Hopkins Arthritis CenterSubcutaneous injection technique: site preparation, needle angle (45–90°), and injection site rotation
• NCBI Bookshelf (Clinical Procedures)Best practices for injection: aseptic technique, site preparation, and administration procedures
• CDC Vaccine AdministrationSubcutaneous injection route guidance: needle angle, site selection, and no aspiration for subcut injections
• PMC (Subcutaneous Drug Injection Review)Pharmacologic and physiologic considerations of the subcutaneous route for drug administration